Dugan E, Blach S, Biondi M, et al. - No treatment has been approved for hepatitis C virus (HCV) infection during pregnancy, but interventions specifically targeting women, especially those of childbearing age (15–49 years) help avert vertical transmission and community spread, so researchers investigated the global prevalence of viraemic HCV in 2019 among women of childbearing age to assess the impact of such interventions. Previously developed models with country-specific demographic and HCV epidemiology data for 110 countries were used in this modelling study. Per estimates, there were 14,860,000 women worldwide (aged 15–49 years) who had HCV infection in 2019, corresponding to a viraemic prevalence of 0.78%. Globally, an increase in HCV prevalence was observed with age, from 0.25% in women aged 15–19 years to 1.21% in women aged 45–49 years. The greatest numbers of viraemic infections were reported in China and Pakistan, however, the highest viraemic prevalence was observed in Mongolia and Burundi. Among the GBD regions, the highest viraemic prevalence was noted in eastern Europe. By WHO region, the Eastern Mediterranean region showed the highest viraemic prevalence. This data can aid in informing preconception test-and-treat strategies to lower vertical transmission and total disease burden.